Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.
The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.
Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.
The Board of Directors of Vimian Group AB has based on the authorisation from the Annual General Meeting on 2 June 2023, resolved on a rights issue of up to approximately SEK 1,633 million. The purpose of the Rights Issue
Read moreOn the 22 of February, the winners of the “CEO of the Year” award were announced at Kistamässan in Stockholm. The winner in the Large-Cap category was David von Laskowski, Picadeli & Greenfood Group. “CEO of the Year” has been
Read moreVegner Group Limited is a leading residential property management group in the UK with 475 employees, over 100,000 homes under management and a nationwide reach across 20 office locations. Vegner specializes in serving Residents Management Company (RMC) clients, bringing further
Read more